HMG CoA reductase inhibitors (statins) for dialysis patients

Sankar D. Navaneethan, Sagar U Nigwekar, Vlado Perkovic, David W. Johnson, Jonathan C. Craig, Giovanni F.M. Strippoli

Research output: Contribution to journalReview article

56 Citations (Scopus)

Abstract

Dialysis patients are at high risk of heart disease. Statins have been shown to decrease cholesterol levels and mortality in the general population. We aimed to determine if a similar effect has been established in dialysis patients. This review identified 14 studies ‐ 13 comparing statins with placebo and one comparing statins to another lipid lowering agent. Statins decreased cholesterol levels to a level similar to that seen in the general population and were safe. One large study did not find any major mortality benefits with statins even though it reduced the number of cardiovascular events in dialysis patients.
Original languageEnglish
Article numberCD004289
JournalCochrane Database of Systematic Reviews
Issue number3
Publication statusPublished - 8 Jul 2009

Keywords

  • dialysis
  • kidney disease
  • cardiovascular disease
  • Statins

Fingerprint Dive into the research topics of 'HMG CoA reductase inhibitors (statins) for dialysis patients'. Together they form a unique fingerprint.

  • Cite this

    Navaneethan, S. D., Nigwekar, S. U., Perkovic, V., Johnson, D. W., Craig, J. C., & Strippoli, G. F. M. (2009). HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews, (3), [CD004289].